Peregrine Capital Management’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $7.67M | Buy |
73,468
+13,747
| +23% | +$1.44M | 0.23% | 126 |
|
|
2025
Q1 | $6.97M | Sell |
59,721
-27,466
| -32% | -$3.2M | 0.23% | 123 |
|
|
2024
Q4 | $7.38M | Buy |
87,187
+15,258
| +21% | +$1.29M | 0.22% | 128 |
|
|
2024
Q3 | $6.46M | Sell |
71,929
-15,444
| -18% | -$1.39M | 0.2% | 159 |
|
|
2024
Q2 | $7.03M | Buy |
87,373
+1,238
| +1% | +$99.7K | 0.21% | 169 |
|
|
2024
Q1 | $6.87M | Buy |
86,135
+1,318
| +2% | +$105K | 0.2% | 177 |
|
|
2023
Q4 | $6.75M | Sell |
84,817
-6,274
| -7% | -$499K | 0.2% | 183 |
|
|
2023
Q3 | $6.37M | Sell |
91,091
-16,442
| -15% | -$1.15M | 0.19% | 212 |
|
|
2023
Q2 | $7.73M | Sell |
107,533
-748
| -0.7% | -$53.8K | 0.21% | 198 |
|
|
2023
Q1 | $6.68M | Buy |
108,281
+11,895
| +12% | +$734K | 0.19% | 224 |
|
|
2022
Q4 | $7.43M | Sell |
96,386
-10,453
| -10% | -$806K | 0.23% | 199 |
|
|
2022
Q3 | $4.77M | Sell |
106,839
-34,445
| -24% | -$1.54M | 0.15% | 235 |
|
|
2022
Q2 | $5.41M | Sell |
141,284
-24,372
| -15% | -$933K | 0.16% | 237 |
|
|
2022
Q1 | $6.86M | Buy |
165,656
+46,358
| +39% | +$1.92M | 0.16% | 231 |
|
|
2021
Q4 | $4.51M | Buy |
119,298
+3,359
| +3% | +$127K | 0.09% | 250 |
|
|
2021
Q3 | $3.82M | Sell |
115,939
-22,996
| -17% | -$758K | 0.08% | 252 |
|
|
2021
Q2 | $9.37M | Buy |
138,935
+10,530
| +8% | +$710K | 0.17% | 240 |
|
|
2021
Q1 | $7.27M | Sell |
128,405
-17,920
| -12% | -$1.01M | 0.13% | 251 |
|
|
2020
Q4 | $11.9M | Buy |
+146,325
| New | +$11.9M | 0.23% | 207 |
|